Neuroinflammation plays a key role in early
brain injury (EBI) of
subarachnoid hemorrhage (SAH), and NLRP3
inflammasome plays an important role in the development of
neuroinflammation after SAH, but the mechanism of NLRP3
inflammasome activation after SAH is still unclear. TRPV1 is a non-selective
calcium channel that is involved in the pathology of
neuroinflammation, but its role in SAH has not been revealed. Our study showed that TRPV1 was significantly upregulated after SAH and was predominantly expressed in microglia/macrophages. Antagonism of TRPV1 was effective in ameliorating neurological impairment,
brain edema, neuronal damage, and reducing the inflammatory response (evidenced by reducing the number of CD16/32 positive microglia/macrophages, inhibiting the expression of CD16, CD32, CD86, IL-1b, TNF-a and blocking NLRP3
inflammasome activation). However, this effect can be abolished by NLRP3
inflammasome antagonist
MCC950. In vitro experiment confirmed that TRPV1 activated NLRP3
inflammasome by increasing intracellular
calcium levels. In conclusion, TRPV1 mediates EBI after SAH via
calcium/NLRP3, and TRPV1 is a potential therapeutic target after SAH.